Letters
Dementia drug funding in France
Deprescribing dementia drugs
BMJ 2020; 368 doi: https://doi.org/10.1136/bmj.m650 (Published 20 February 2020) Cite this as: BMJ 2020;368:m650
- Steve Iliffe, emeritus professor of primary care for older people1,
- Jill Manthorpe, professor of social work and director2
- 1Centre for Ageing Population Studies, University College London, Royal Free Campus, London NW3 2PF, UK
- 2NIHR Health and Social Care Workforce Research Unit, King’s College London, London, UK
- s.iliffe{at}ucl.ac.uk
Twenty years ago Prescrire International said that the effects of cholinesterase inhibitors were “only moderate and of doubtful clinical significance.”1 Nothing much has changed, judging by the French government’s decision to stop reimbursing this group of drugs, as discussed by Walsh and colleagues.2 The cholinesterase inhibitors and memantine seem effective for some people, but their benefits seem negligible in the population.3 The …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.